MA40027A - Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique - Google Patents

Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique

Info

Publication number
MA40027A
MA40027A MA040027A MA40027A MA40027A MA 40027 A MA40027 A MA 40027A MA 040027 A MA040027 A MA 040027A MA 40027 A MA40027 A MA 40027A MA 40027 A MA40027 A MA 40027A
Authority
MA
Morocco
Prior art keywords
agonist
beta
pharmaceutical composition
anticholinergic agent
anticholinergic
Prior art date
Application number
MA040027A
Other languages
English (en)
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MA40027A publication Critical patent/MA40027A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques à inhaler qui comprennent un ou plusieurs bronchodilatateurs.
MA040027A 2014-06-18 2015-06-18 Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique MA40027A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1969MU2014 2014-06-18

Publications (1)

Publication Number Publication Date
MA40027A true MA40027A (fr) 2015-12-23

Family

ID=53762205

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040027A MA40027A (fr) 2014-06-18 2015-06-18 Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique

Country Status (6)

Country Link
US (1) US20170119744A1 (fr)
EP (1) EP3157567A1 (fr)
AU (1) AU2015275933A1 (fr)
CA (1) CA2952760A1 (fr)
MA (1) MA40027A (fr)
WO (1) WO2015193631A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3880169B1 (fr) * 2018-11-12 2025-07-23 Kindeva Drug Delivery L.P. Formulation d'umeclidinium et vilanterol et inhalateur
US20220241524A1 (en) * 2019-07-12 2022-08-04 Kindeva Drug Delivery L.P. Aerosol formulation, canister, and inhaler containing the formulation, and method of use
WO2021009573A1 (fr) * 2019-07-12 2021-01-21 Kindeva Drug Delivery L.P. Formulation d'aérosol, cartouche et inhalateur contenant la formulation, et procédé d'utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
KR20100063116A (ko) 2007-09-12 2010-06-10 글락소 그룹 리미티드 치료제들의 복합제
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
BR112013031570A2 (pt) 2011-06-08 2017-03-21 Glaxo Group Ltd inalador de pó seco.
WO2012168161A1 (fr) 2011-06-08 2012-12-13 Glaxo Group Limited Combinaison comprenant de l'uméclidinium et un corticoïde
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
EP2668941A1 (fr) 2012-05-31 2013-12-04 Almirall, S.A. Nouveau dosage et formulation d'abediterol
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
US9700558B2 (en) * 2013-03-15 2017-07-11 Verona Pharma Plc Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
PE20160198A1 (es) 2013-07-30 2016-04-21 Glaxosmithkline Ip Dev Ltd Composiciones topicas para el tratamiento de sudoracion excesiva y metodos para utilizar las mismas

Also Published As

Publication number Publication date
WO2015193631A1 (fr) 2015-12-23
AU2015275933A1 (en) 2017-02-02
EP3157567A1 (fr) 2017-04-26
CA2952760A1 (fr) 2015-12-23
US20170119744A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
PT3513809T (pt) Composição medicinal compreendendo tivozanib
IL271657A (en) medical preparation
GEP20217239B (en) Pharmaceutical composition
GB201608323D0 (en) Pharmaceutical compositions
WO2015120062A3 (fr) Composés et compositions thérapeutiques
EP3221341A4 (fr) Compositions à variant thérapeutique d'alpha-2-macroglobuline
GEP20217240B (en) Pharmaceutical composition
GB201705303D0 (en) Pharmaceutical compositions
GB201506526D0 (en) Medicinal composition
MX379126B (es) Formulación de factor viii.
GB201705304D0 (en) Pharmaceutical compositions
SG11202001179YA (en) Pharmaceutical compositions
MX371443B (es) Composiciones farmaceuticas que comprenden levocetirizina.
GB201705305D0 (en) Pharmaceutical compositions
GB201705306D0 (en) Pharmaceutical compositions
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
GB201615917D0 (en) Pharmaceutical composition
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
GB201615914D0 (en) Pharmaceutical composition
ZA202000014B (en) Pharmaceutical compositions
WO2015108945A3 (fr) Compositions et méthodes pour l'administration d'agents thérapeutiques
IL263999A (en) Pharmaceutical compositions
GB201615910D0 (en) Pharmaceutical composition
IL272044A (en) Pharmacy preparations